The recent Facebook controversy is not the first problem digital ad spending has seen and it will not be the last. These three players stand to suffer as advertisers put the brakes on this form of advertising. Read More
Linda McDonough is a veteran hedge fund analyst who loves to break down company financial statements and identify market inefficiencies to uncover big opportunities. She believes in a boots-on-the-ground approach that includes surveying customers, interviewing company executives, or doing whatever it takes to see what others don't.
She's now brought her experience as a hedge fund analyst to subscribers of her Profit Catalyst Alert service. Her system identifies small- and mid-cap stocks that are about to move due to catalytic events that few others can identify...until it's too late. These events often times result in massive gains for her followers.
Analyst Articles
Carbonite soars on investor excitement over cloud security, SmartSand gets smacked for expansion and more... Read More
Buy Harsco. Idle steel and metal plants are being re-opened in the U.S. and will need someone to help maintain those plants. Harsco is just the company. Read More
Big Lots' issuance of a weak first quarter and full year guidance sent the stock tumbling. As predicted, soft furniture sales were the culprit. Target still felt the wrath of sellers despite a good quarter- analysis on both these stocks and more in this week's update. Read More
The Chemours Company was a big winner for us last year and my concern of waning Opteon demand was premature. Demand from new European grocery stores and domestic auto producers should buoy the stock. Read More
Big Lots competitor Dollar Tree reported weak sales and earnings today and is pulling down the group. While Big Lots may still drop significantly this Friday when it reports fourth-quarter earnings, I suggest booking this significant gain. Read More
Facebook's management is bullish long-term but admits 2018 might be a tricky year. ANI Pharma gets one step closer to manufacturing a blockbuster drug and Target is on deck for earnings this week. Read More
Facebook has dropped partly due to a less-than-exuberant management presentation and partly due to the market malaise. Either way, book this fabulous one-week gain. Read More
It's been a rough two-weeks for my option trade suggestions. A bit of thought regarding those positions and news coming this week on put position Facebook. Read More
It may sound like heresy to short market darling Facebook but it looks like it's hitting some major stumbling blocks. I expect the stock to stumble during its upcoming February presentation at a significant investor conference. Read More